<DOC>
	<DOCNO>NCT00130351</DOCNO>
	<brief_summary>This study design investigate ability patient asthma properly use new multi-dose dry powder inhaler ( MDDPI ) device real-life situation .</brief_summary>
	<brief_title>A 3-week Study Investigating Patient Use Functionality Formoterol Novel Inhalation Device Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Patients capable understanding direction device usage , evaluate device function complete patient diary Patients current diagnosis asthma Patients document forced expiratory volume 1 second ( FEV1 ) reversibility least 12 % baseline value follow administration bronchodilator ( i.e . `` historical '' reversibility ) demonstrate &gt; 12 % increase FEV1 baseline value within 30 minute inhalation 360 µg ( 4 puff ) albuterol Visit 1 . The administration albuterol reversibility test must within 30 minute baseline spirometry . Patients enrol study CFOR258F2304 CFOR258F2306 , experience use Certihaler® device . QTc 450 millisecond male 470 millisecond female , finding screen electrocardiogram ( ECG ) opinion investigator would present safety hazard continuation study Patients known history untoward reaction sympathomimetic amine inhale medication individual component therapies Other protocoldefined inclusion exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>asthma , formoterol multi-dose dry powder inhaler ( MDDPI )</keyword>
</DOC>